Physician profile
Dennis Johnson
NPI 1972512432
$1,613.03
in general payments reported to CMS, 2019-2025
17 companies · $182 in 2025
The $182 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $968 · 2020: $135 · 2021: $89.98 · 2022: $33.51 · 2023: $40.07 · 2024: $164 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $386.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Artivion, INC. | $662.12 | 2019 | |
| Amgen INC. | $332.68 | 2019-2025 | Repatha |
| Edwards Lifesciences Corporation | $119.18 | 2019 | |
| Lantheus Medical Imaging, INC. | $100.00 | 2019 | |
| Cvrx, INC. | $87.84 | 2024 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $51.56 | 2021-2024 | |
| Philips North America LLC | $50.22 | 2021 | |
| Pfizer INC. | $28.87 | 2025 | |
| Alnylam Pharmaceuticals INC. | $26.90 | 2025 | Amvuttra |
| Boston Scientific Corporation | $26.37 | 2023 | Watchman Flx |
| Abiomed | $21.58 | 2024 | Impella |
| Chiesi USA, INC. | $21.00 | 2021 | |
| Merck Sharp & Dohme LLC | $18.95 | 2024 | Verquvo |
| Astrazeneca Pharmaceuticals Lp | $18.84 | 2024 | Farxiga |
| Bard Peripheral Vascular, INC. | $17.47 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $15.75 | 2025 | Zepbound |
| Novo Nordisk INC | $13.70 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.